{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:56:52Z","timestamp":1791755812721,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"DOI":"10.7759\/cureus.103385","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:50:32Z","timestamp":1770785432000},"source":"Crossref","is-referenced-by-count":1,"title":["Hyperprolactinemia in Older Adults: A Narrative Review of Distinct Clinical Challenges and Management Strategies"],"prefix":"10.7759","author":[{"given":"Andres F","family":"Quimbayo-Cifuentes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed S","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96:273-88. 10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","article-title":"Prolactin--not only lactotrophin. A \"new\" view of the \"old\" hormone","volume":"63","author":"Ignacak A","year":"2012","unstructured":"Ignacak A, Kasztelnik M, Sliwa T, Korbut RA, Rajda K, Guzik TJ. Prolactin--not only lactotrophin. A \"new\" view of the \"old\" hormone. J Physiol Pharmacol. 2012, 63:435-43.","journal-title":"J Physiol Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-214","article-title":"Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)","volume":"13","author":"Kelly DL","year":"2013","unstructured":"Kelly DL, Wehring HJ, Earl AK, et al.. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013, 13:214. 10.1186\/1471-244X-13-214","journal-title":"BMC Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos NA","year":"2023","unstructured":"Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023, 329:1386-98. 10.1001\/jama.2023.5444","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu M","year":"2025","unstructured":"Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S. Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2025, 13:874-90. 10.1016\/S2213-8587(25)00227-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-351x(97)80377-1","article-title":"Pituitary tumours in the elderly","volume":"11","author":"Turner HE","year":"1997","unstructured":"Turner HE, Wass JA. Pituitary tumours in the elderly. Baillieres Clin Endocrinol Metab. 1997, 11:407-22. 10.1016\/s0950-351x(97)80377-1","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01959-0","article-title":"Pituitary adenomas in elderly patients: clinical and surgical outcome analysis in a large series","volume":"65","author":"Spina A","year":"2019","unstructured":"Spina A, Losa M, Mortini P. Pituitary adenomas in elderly patients: clinical and surgical outcome analysis in a large series. Endocrine. 2019, 65:637-45. 10.1007\/s12020-019-01959-0","journal-title":"Endocrine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01962-5","article-title":"Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years","volume":"65","author":"Shimon I","year":"2019","unstructured":"Shimon I, Hirsch D, Tsvetov G, et al.. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine. 2019, 65:656-61. 10.1007\/s12020-019-01962-5","journal-title":"Endocrine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109941","article-title":"Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management","volume":"101","author":"Gonz\u00e1lez-Rodr\u00edguez A","year":"2020","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Labad J, Seeman MV. Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry. 2020, 101:109941. 10.1016\/j.pnpbp.2020.109941","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2095","article-title":"Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi E","year":"2010","unstructured":"Valassi E, Klibanski A, Biller BM. Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010, 95:1025-33. 10.1210\/jc.2009-2095","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031305","article-title":"Prolactin secretion in healthy adults is determined by gender, age and body mass index","volume":"7","author":"Roelfsema F","year":"2012","unstructured":"Roelfsema F, Pijl H, Keenan DM, Veldhuis JD. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One. 2012, 7:e31305. 10.1371\/journal.pone.0031305","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran S","year":"2001","unstructured":"Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001, 54:295-300. 10.1046\/j.1365-2265.2001.01190.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09890-0","article-title":"Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study","volume":"25","author":"Han TS","year":"2024","unstructured":"Han TS, Antonio L, Bartfai G, et al.. Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study. Rev Endocr Metab Disord. 2024, 25:1097-107. 10.1007\/s11154-024-09890-0","journal-title":"Rev Endocr Metab Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.3.5514","article-title":"Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval--a General Clinical Research Center study","volume":"84","author":"Iranmanesh A","year":"1999","unstructured":"Iranmanesh A, Mulligan T, Veldhuis JD. Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval--a General Clinical Research Center study. J Clin Endocrinol Metab. 1999, 84:1083-90. 10.1210\/jcem.84.3.5514","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre DL","year":"2007","unstructured":"Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007, 3:929-51.","journal-title":"Ther Clin Risk Manag"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-023-00462-2","article-title":"Clinical presentations of drug-induced hyperprolactinaemia: a literature review","volume":"37","author":"Junqueira DR","year":"2023","unstructured":"Junqueira DR, Bennett D, Huh SY, Casa\u00f1as I Comabella C. Clinical presentations of drug-induced hyperprolactinaemia: a literature review. Pharmaceut Med. 2023, 37:153-66. 10.1007\/s40290-023-00462-2","journal-title":"Pharmaceut Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2017.02.003","article-title":"Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics","volume":"45","author":"Montejo \u00c1L","year":"2017","unstructured":"Montejo \u00c1L, Arango C, Bernardo M, et al.. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017, 45:25-34. 10.1016\/j.yfrne.2017.02.003","journal-title":"Front Neuroendocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2017-135221","article-title":"Antipsychotic-induced hyperprolactinaemia: case studies and review","volume":"94","author":"Mittal S","year":"2018","unstructured":"Mittal S, Prasad S, Ghosh A. Antipsychotic-induced hyperprolactinaemia: case studies and review. Postgrad Med J. 2018, 94:226-9. 10.1136\/postgradmedj-2017-135221","journal-title":"Postgrad Med J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02803-z","article-title":"Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting","volume":"397","author":"Garc\u00eda Cano AM","year":"2024","unstructured":"Garc\u00eda Cano AM, Rosillo M, G\u00f3mez Lozano A, Jim\u00e9nez Mendiguch\u00eda L, March\u00e1n Pinedo M, Rodr\u00edguez Torres A, Araujo-Castro M. Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting. Naunyn Schmiedebergs Arch Pharmacol. 2024, 397:3239-46. 10.1007\/s00210-023-02803-z","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.791283","article-title":"Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences","volume":"9","author":"Voicu V","year":"2013","unstructured":"Voicu V, Medvedovici A, Ranetti AE, R\u0103dulescu F\u015e. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences. Expert Opin Drug Metab Toxicol. 2013, 9:955-68. 10.1517\/17425255.2013.791283","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref21","article-title":"Pharmacological causes of hyperprolactinemia","author":"Kolnikaj TS","year":"2024","unstructured":"Kolnikaj TS, Musat M, Salehidoost R, Korbonits M. Pharmacological causes of hyperprolactinemia. Endotext [Internet]. Feingold KR, Adler RA, Ahmed SF, et al. (ed): MDText.com, Inc., South Dartmouth (MA); 2024."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1996.270.1.E96","article-title":"Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia","volume":"270","author":"Kelley SR","year":"1996","unstructured":"Kelley SR, Kamal TJ, Molitch ME. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol. 1996, 270:E96-100. 10.1152\/ajpendo.1996.270.1.E96","journal-title":"Am J Physiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6019.1186","article-title":"Effects of methyldopa on prolactin and growth hormone","volume":"1","author":"Steiner J","year":"1976","unstructured":"Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A. Effects of methyldopa on prolactin and growth hormone. Br Med J. 1976, 1:1186-8. 10.1136\/bmj.1.6019.1186","journal-title":"Br Med J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2021.03.010","article-title":"Prolactin and other pituitary disorders in kidney disease","volume":"41","author":"Huang W","year":"2021","unstructured":"Huang W, Molitch ME. Prolactin and other pituitary disorders in kidney disease. Semin Nephrol. 2021, 41:156-67. 10.1016\/j.semnephrol.2021.03.010","journal-title":"Semin Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omac006","article-title":"Case report: cause of hyperprolactinemia in an elderly patient","volume":"2022","author":"Moslehi S","year":"2022","unstructured":"Moslehi S, Iliff J, Goudaman S. Case report: cause of hyperprolactinemia in an elderly patient. Oxf Med Case Reports. 2022, 2022:omac006. 10.1093\/omcr\/omac006","journal-title":"Oxf Med Case Reports"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01081-9","article-title":"Pituitary adenomas in older adults (\u2265\u200965\u00a0years): 90-day outcomes and readmissions: a 10-year endoscopic endonasal surgical experience","volume":"24","author":"Thakur JD","year":"2021","unstructured":"Thakur JD, Corlin A, Mallari RJ, et al.. Pituitary adenomas in older adults (\u2265\u200965\u00a0years): 90-day outcomes and readmissions: a 10-year endoscopic endonasal surgical experience. Pituitary. 2021, 24:14-26. 10.1007\/s11102-020-01081-9","journal-title":"Pituitary"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000506810","article-title":"Metastatic spread to the pituitary","volume":"110","author":"Shimon I","year":"2020","unstructured":"Shimon I. Metastatic spread to the pituitary. Neuroendocrinology. 2020, 110:805-8. 10.1159\/000506810","journal-title":"Neuroendocrinology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040585","article-title":"Ovarian cancer causing hyperprolactinemia: a case report and narrative review","volume":"104","author":"\u0160akinien\u0117 S","year":"2025","unstructured":"\u0160akinien\u0117 S, Veli\u010dkien\u0117 D. Ovarian cancer causing hyperprolactinemia: a case report and narrative review. Medicine (Baltimore). 2025, 104:e40585. 10.1097\/MD.0000000000040585","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09870-w","article-title":"Diagnosing and treating the elderly individual with hypopituitarism","volume":"25","author":"Corsello A","year":"2024","unstructured":"Corsello A, Paragliola RM, Salvatori R. Diagnosing and treating the elderly individual with hypopituitarism. Rev Endocr Metab Disord. 2024, 25:575-97. 10.1007\/s11154-023-09870-w","journal-title":"Rev Endocr Metab Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2014.10.013","article-title":"Importance of macroprolactinemia in hyperprolactinemia","volume":"183","author":"Kasum M","year":"2014","unstructured":"Kasum M, Pavi\u010di\u0107-Baldani D, Stani\u0107 P, Ore\u0161kovi\u0107 S, Sari\u0107 JM, Blaji\u0107 J, Juras J. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 2014, 183:28-32. 10.1016\/j.ejogrb.2014.10.013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0460","article-title":"Interference by macroprolactin in assays for prolactin: will the In\u00a0Vitro Diagnostics Regulation lead to a solution at last?","volume":"60","author":"Fahie-Wilson MN","year":"2022","unstructured":"Fahie-Wilson MN, Cobbaert CM, Horvath AR, Smith TP. Interference by macroprolactin in assays for prolactin: will the In\u00a0Vitro Diagnostics Regulation lead to a solution at last?. Clin Chem Lab Med. 2022, 60:1350-5. 10.1515\/cclm-2022-0460","journal-title":"Clin Chem Lab Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17218199","article-title":"Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"17","author":"Che Soh NA","year":"2020","unstructured":"Che Soh NA, Yaacob NM, Omar J, et al.. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2020, 17:8199. 10.3390\/ijerph17218199","journal-title":"Int J Environ Res Public Health"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/BF03324902","article-title":"Hypopituitarism in the elderly: two case-reports with heterogeneous presentation","volume":"21","author":"Foppiani L","year":"2009","unstructured":"Foppiani L, Ruelle A, Quilici P, Del Monte P. Hypopituitarism in the elderly: two case-reports with heterogeneous presentation. Aging Clin Exp Res. 2009, 21:76-81. 10.1007\/BF03324902","journal-title":"Aging Clin Exp Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2021.06.014","article-title":"Hyperprolactinemia after menopause: diagnosis and management","volume":"151","author":"Auriemma RS","year":"2021","unstructured":"Auriemma RS, Pirchio R, Pivonello R, Colao A. Hyperprolactinemia after menopause: diagnosis and management. Maturitas. 2021, 151:36-40. 10.1016\/j.maturitas.2021.06.014","journal-title":"Maturitas"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(sup01)09","article-title":"Hypogonadotropic hypogonadism revisited","volume":"68","author":"Fraietta R","year":"2013","unstructured":"Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics (Sao Paulo). 2013, 68:81-8. 10.6061\/clinics\/2013(sup01)09","journal-title":"Clinics (Sao Paulo)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01041-3","article-title":"Hyperprolactinemia and bone","volume":"23","author":"di Filippo L","year":"2020","unstructured":"di Filippo L, Doga M, Resmini E, Giustina A. Hyperprolactinemia and bone. Pituitary. 2020, 23:314-21. 10.1007\/s11102-020-01041-3","journal-title":"Pituitary"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101624","article-title":"Role of sex steroids hormones in the regulation of bone metabolism in men: evidence from clinical studies","volume":"36","author":"Szulc P","year":"2022","unstructured":"Szulc P. Role of sex steroids hormones in the regulation of bone metabolism in men: evidence from clinical studies. Best Pract Res Clin Endocrinol Metab. 2022, 36:101624. 10.1016\/j.beem.2022.101624","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker MD","year":"2023","unstructured":"Walker MD, Shane E. Postmenopausal osteoporosis. N Engl J Med. 2023, 389:1979-91. 10.1056\/NEJMcp2307353","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00025","article-title":"Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology","volume":"7","author":"Torner L","year":"2016","unstructured":"Torner L. Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology. Front Endocrinol (Lausanne). 2016, 7:25. 10.3389\/fendo.2016.00025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002252","article-title":"Cognitive functioning of patients with a PRL-secreting pituitary adenoma: a preliminary report","volume":"86","author":"Bala A","year":"2016","unstructured":"Bala A, \u0141ojek E, Marchel A. Cognitive functioning of patients with a PRL-secreting pituitary adenoma: a preliminary report. Neurology. 2016, 86:731-4. 10.1212\/WNL.0000000000002252","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16208","article-title":"The utility of rested prolactin sampling in the evaluation of hyperprolactinaemia","volume":"54","author":"Wilkinson T","year":"2024","unstructured":"Wilkinson T, Li B, Soule S, Hunt P. The utility of rested prolactin sampling in the evaluation of hyperprolactinaemia. Intern Med J. 2024, 54:307-11. 10.1111\/imj.16208","journal-title":"Intern Med J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.31031\/GGS.2017.01.000513","article-title":"Hypopituitarism associated with a microadenoma in an elderly patient","volume":"1","author":"Tasar PT","year":"2017","unstructured":"Tasar PT, Turhan A, Binici DN, Sahin S, Timur O. Hypopituitarism associated with a microadenoma in an elderly patient. Gerontol Geriatr Stud. 2017, 1:10.31031\/GGS.2017.01.000513","journal-title":"Gerontol Geriatr Stud"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:22:3:267","article-title":"Macroprolactinemia: the consequences of a laboratory pitfall","volume":"22","author":"Toldy E","year":"2003","unstructured":"Toldy E, L\u00f6csei Z, Szabolcs I, G\u00f3th MI, Kneffel P, Sz\u00f6ke D, Kov\u00e1cs GL. Macroprolactinemia: the consequences of a laboratory pitfall. Endocrine. 2003, 22:267-73. 10.1385\/ENDO:22:3:267","journal-title":"Endocrine"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01246-8","article-title":"Prolactin immunoassay: does the high-dose hook effect still exist?","volume":"25","author":"Raverot V","year":"2022","unstructured":"Raverot V, Perrin P, Chanson P, Jouanneau E, Brue T, Raverot G. Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary. 2022, 25:653-7. 10.1007\/s11102-022-01246-8","journal-title":"Pituitary"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter D","year":"2014","unstructured":"Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014, 170:R213-27. 10.1530\/EJE-14-0013","journal-title":"Eur J Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-33","article-title":"Treatment of hyperprolactinemia: a systematic review and meta-analysis","volume":"1","author":"Wang AT","year":"2012","unstructured":"Wang AT, Mullan RJ, Lane MA, et al.. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012, 1:33. 10.1186\/2046-4053-1-33","journal-title":"Syst Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.1152","article-title":"7173 cabergoline induced psychosis in a patient with no previous history of psychiatric disorder","volume":"8","author":"Aryal B","year":"2024","unstructured":"Aryal B, Kim KY, Shafi A, Ganesh M. 7173 cabergoline induced psychosis in a patient with no previous history of psychiatric disorder. J Endocr Soc. 2024, 8:10.1210\/jendso\/bvae163.1152","journal-title":"J Endocr Soc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440301-hyperprolactinemia-in-older-adults-a-narrative-review-of-distinct-clinical-challenges-and-management-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:50:33Z","timestamp":1770785433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440301-hyperprolactinemia-in-older-adults-a-narrative-review-of-distinct-clinical-challenges-and-management-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.103385","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}